Skip to main content
SpringerLink
Log in

Heterogeneity ofin vitro chemosensitivity in perioperative breast cancer cells to mitoxantroneversus doxorubicin evaluated by a microplate ATP bioluminescence assay

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Apart from clinical trials, mitoxantrone (MX) is rarely used in breast cancer (BC) due to the anticipated anthracycline cross-resistance. We have examined this drug versus doxorubicin (DOX) using data obtained fromin vitro microplate ATP tumor chemosensitivity assays (ATP-TCA) of BC cells which were derived from 55 chemotherapy-naive patients at time of primary surgery. Both drugs were tested at 6 different concentrations ranging from 6.25% to 200% peak plasma concentrationin vivo (PPC). Differences between DOX and MX observed for mean IC50, IC90, and a sensitivity index (SI) were not statistically significant.In vitro response rates were 44% for DOX and 52% for MX. 34 of 52 eligible assays (65%) showed comparable activity of both drugs whereas a lack of cross-resistance was observed in the remaining 18 (35%) tumors as indicated by differences for SI. Cumulative concentration-response plots of tumors respondingin vitro with a ≥ 50 percent or ≥ 90 percent tumor cell inhibition showed a strong dose-dependence for both DOX and MX at concentrations which normally can be achieved within clinical tumors (i.e. 6.25%-50% PPC). At higher concentrations, however, cytotoxicity of DOX and MX could not be improved by furtherin vitro dose escalation. Moreover, a substantial proportion of BC specimens (DOX: 48.1%; MX: 40.4%) did not experience a ≥ 90 tumor cell inhibition at 200% PPC. In conclusion,in vitro results obtained by ATP-TCA indicate that there is no cross-resistance between MX and DOX in a substantial proportion of BC patients. This may be clinically useful and suggests that combinations including MX should be tested in patients clinically resistant to DOX containing regimens. Since both drugs produced sigmoidal concentration-response curves, dose escalation beyond a certain point may not produce increased sensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fisher B, Carbone P, Economou SG: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292: 117–122, 1975

    PubMed  Google Scholar 

  2. Bonadonna G, Brusamolino E, Valagussa P: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410, 1976

    PubMed  Google Scholar 

  3. Bonadonna G, Valagussa P: The contribution of medicine to the primary treatment of breast cancer. Cancer Res 48: 2314–2324, 1988

    PubMed  Google Scholar 

  4. Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52: 2127–2137, 1992

    PubMed  Google Scholar 

  5. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332: 901–906, 1995

    PubMed  Google Scholar 

  6. Jones RB, Holland JF, Bhardwaj S et al.: A phase I–II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 5: 172–177, 1987

    PubMed  Google Scholar 

  7. Ahman DL, Schaid D, Bisel HF: The effect on survival of initiating chemotherapy in advanced breast cancer: polychemotherapy versus single drug. J Clin Oncol 5: 1928–1932, 1987

    PubMed  Google Scholar 

  8. Kardinal CG: Chemotherapy of breast cancer. In: Perry MC (ed.) The Chemotherapy Source Book. Williams & Wilkins, Baltimore, 1992, pp 949–988

    Google Scholar 

  9. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG, Shibata H, Paterson AHG, Sutherland CM, Robert NJ, Ager PJ, Levy L, Wolter J, Wozniak T, Fisher ER, Deutsch M: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483–1496, 1990

    PubMed  Google Scholar 

  10. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood W, Barcos M, Henderson C: C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260–1266, 1994

    PubMed  Google Scholar 

  11. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JA-MA 273: 542–547, 1995

    Google Scholar 

  12. Dukart G, Iatropoulos MJ, Yacobi A: Comment on mitoxantrone. Drug Intell Clin Pharmacy 19: 216–218, 1985

    Google Scholar 

  13. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560–571, 1989

    PubMed  Google Scholar 

  14. Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger K, Kunz S, Neeser E, von Ingersleben G, Hossfeld D, Caffier H, Souchon R, Waldmann R, Blümner E, Clark J: Prognostic subgroups: The key factor for treatment outcome in metastatic breast cancer. Results of a three-arm randomized multicenter trial comparing doxorubicin, epirubicin and mitoxantrone each in combination with cyclophosphamide. Onkologie 16: 344–353, 1993

    Google Scholar 

  15. Smith IE: Mitoxantrone (novantrone): A review of experimental and early clinical studies. Cancer Treat Rev 10: 103–115, 1983

    Google Scholar 

  16. Neidhart JA, Gochnour D, Roach R, Hoth D, Young D: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 672–677, 1986

    PubMed  Google Scholar 

  17. Andersson M, Mouridsen HT: Mitoxantrone as single agent chemotherapeutic agent for advanced breast cancer: The phase II trial experience. In: Mouridsen HT, Arlin ZA (eds) The Role of Mitoxantrone in Malignant Diseases. Pharma-Libri Publ, Chicago, 1987, pp 31–47

    Google Scholar 

  18. Ahmann F, Garewal H, Schifman R, Celniker A, Rodney S: Intracellular adenosine triphosphate as a measure of human cell viability and drug modulated growth.In vitro Cell Develop Biol 23: 474–480, 1987

    Google Scholar 

  19. Andreotti PE, Linder D, Hartmann DM, Becker K, Herbst K, Cree IA, Bruckner HW: ATP tumor chemosensitivity assay application for solid tumors and leukemias. In: Szalay A, Kricka LJ, Stanley PE (eds) Chemiluminescence and Bioluminescence. Status Report. John Wiley & Sons: Chichester, 1993, pp 271–275

    Google Scholar 

  20. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Wood RAB, Linder D, Andreotti PE: Heterogeneity of chemosensitivity in human breast carcinoma: Use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 19: 242–249, 1993

    PubMed  Google Scholar 

  21. Petty RD, Sutherland LA, Hunter EM, Cree IA: Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 10: 29–34, 1995

    PubMed  Google Scholar 

  22. Sevin BU, Peng Z, Perras J, Ganjei P, Penalver G, Averette H: Application of an ATP bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 31: 191–204, 1988

    PubMed  Google Scholar 

  23. Andreotti PE, Thornwaite JT, Morse IS: ATP tumor chemosensitivity assay. In: Stanley PE, Kricka LJ (eds) Bioluminescence and Chemiluminescence: Current Status. John Wiley & Sons, Chichester, 1991, pp 417–420

    Google Scholar 

  24. Cree IA, Pazzagli M, Mini E, Mazzei T, Hunter EMM, Sutherland LA, Pinzani P, Gerli A, Andreotti PE: Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anti-Cancer Drugs 6: 398–404, 1995

    PubMed  Google Scholar 

  25. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW: TCA-100 Tumor Chemosensitivity Assay: Differences in sensitivity between cultured tumour cell lines and clinical studies. J Biolumin Chemilumin 9: 373–378, 1994

    PubMed  Google Scholar 

  26. Kurbacher CM, Bruckner HW, Andreotti PE, Kurbacher JA, Sa G, Krebs D:In vitro activity of titanocenedichloride versus cisplatin in four ovarian carcinoma cell lines evaluated by a microtitre plate ATP bioluminescence assay. Anti-Cancer Drugs 6: 697–704, 1995

    PubMed  Google Scholar 

  27. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Bruckner HW: Sensitivity testing of human tumors using a microplate ATP assay. In: Campbell AK, Kricka LJ, Stanley PE (eds) Bioluminescence and Chemiluminescence. Fundamentals and Applied Aspects. John Wiley & Sons, Chichester, 1994, pp 403–406

    Google Scholar 

  28. Kurbacher CM, Mallmann P, Kurbacher JA, Saß G, Andreotti PE, Rahmun A, Hübner H, Krebs D:In vitro activity of titanocenedichlorideversus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer. Anticancer Res 14: 1961–1966, 1994

    PubMed  Google Scholar 

  29. Koechli OR, Avner BP, Sevin BU, Avner B, Perras JP, Robinson DS, Averette HE: Application of the ATP-Cell Viability Assay in human breast cancer chemosensitivity testing. A report on the first results. J Surg Oncol 54: 119–125, 1993

    PubMed  Google Scholar 

  30. Cree IA, Sutherland LA, Hunter EMM, Subedi AMC, James EA, Dewar JA, Preece PE, Andreotti PE: Validation of the TCA-100 tumour chemosensitivity assay (Abstract). J Tumor Marker Oncol 9: 42, 1994

    Google Scholar 

  31. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, Sartori C, Bruckner HW: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55: 5276–5282, 1995

    PubMed  Google Scholar 

  32. Bosanquet AG: Stability of solutions for antineoplastic agents during preparation and storage forin vitro assays. II. Assay methods, adriamycin and other anti-tumour antibiotics. Cancer Chemother Pharmacol 17: 1–10, 1986

    PubMed  Google Scholar 

  33. Hunter EM, Sutherland LA, Cree IA, Subedi AM, Hartmann D, Linder D, Andreotti PE: The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anti-Cancer Drugs 5: 171–176, 1994

    PubMed  Google Scholar 

  34. Alberts DS: Tabular summary of pharmacokinetic parameters relevant toin vitro drug assay. In: Salmon SE (ed.) Cloning of Human Tumor Stem Cells. Alan R Liss Inc, New York, 1980, pp 351–359

    Google Scholar 

  35. Dalton WS, Alberts DS: Pharmacokinetics of mitoxantrone. In: Mouridsen HT, Arlin ZA (eds) The Role of Mitoxantrone in Malignant Diseases. PharmaLibri Publ, Chicago, 1987, pp 5–18

    Google Scholar 

  36. Silverman RA: Calculus with Analytical Geometry. Prentice Hall Inc., New Yersey, 1985, pp 416–418

    Google Scholar 

  37. Von Hoff DD, Clark GM, Weiss GR, Marshall MH, Buckok JB, Knight WA III, LeMaistre CF: Use ofin vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 4: 1827–1834, 1986

    PubMed  Google Scholar 

  38. Maltere P, Martin M, Piot M, Manoux D, Maillart P, Combe M, Kamioner D, Serin D, Chalmin B, Renaud R, Grapin JP: Neoadjuvant chemotherapy with FNC (fluorouracil, mitoxantrone and cyclophosphamide) in operable locally advanced breast cancer (LABC) allows breast conservation (Abstract). Proc Amer Soc Clin Oncol 14: 92, 1995

    Google Scholar 

  39. Sandbach J, Von Hoff DD, Clark G, Cruz AB, O'Brien M: Direct cloning of human breast cancer in soft agar culture. Cancer 50: 1315–1321, 1982

    PubMed  Google Scholar 

  40. Jones SE, Dean JC, Young LA, Salmon SE: The human tumor clonogenic assay in breast cancer. J Clin Oncol 3: 92–97, 1985

    PubMed  Google Scholar 

  41. Koechli OR, Sevin BU, Perras J, Angioli R, Steren A, Rodriguez M, Averette HE: Growth characteristics of non-malignant cells in the ATP-Cell-Viability-Assay. Oncology 51: 35–41, 1994

    PubMed  Google Scholar 

  42. Riggs CE: Antitumor antibiotics and related compounds. In: Perry MC (ed.) The Chemotherapy Source Book. Williams & Wilkins, Baltimore, 1992, pp 318–358

    Google Scholar 

  43. Fields K, Perkins J, Elfenbein G, Ballester O, Hiemenz J, Goldstein S, Zorsky P, Kronish L: A phase I dose escalation trial of high dose taxol®, novantrone®, and thiotepa (TNT) followed by autologous stem cell rescue (ASCR): Toxicity. (Abstract). Proc Amer Soc Clin Oncol 14: 322, 1995

    Google Scholar 

Download references

Author information

Author notes

  1. Ian A. Cree

    Present address: Institute of Ophthalmology, Department of Pathology, University of London, EC1V 9EL, London, UK

Authors and Affiliations

  1. Universitäts-Frauenklinik, D-53105, Bonn, Germany

    Christian M. Kurbacher, Ursula Brenne, Jutta A. Kurbacher, Peter Mallmann & Dieter Krebs

  2. Tumour Chemosensitivity Laboratory, Department of Pathology, University of Dundee, Ninewells Hospital and Medical School, DD1 9SY, Dundee, UK

    Ian A. Cree

  3. Div. of Neoplastic Diseases, Mt. Sinai School of Medicine, 10029, New York, NY, USA

    Howard W. Bruckner

  4. Atlantic Scientific Development, Inc., 33428, Boca Raton, FL, USA

    Peter E. Andreotti

Authors
  1. Christian M. Kurbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian A. Cree
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ursula Brenne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Howard W. Bruckner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jutta A. Kurbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Mallmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter E. Andreotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dieter Krebs
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurbacher, C.M., Cree, I.A., Brenne, U. et al. Heterogeneity ofin vitro chemosensitivity in perioperative breast cancer cells to mitoxantroneversus doxorubicin evaluated by a microplate ATP bioluminescence assay. Breast Cancer Res Tr 41, 161–170 (1996). https://doi.org/10.1007/BF01807161

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01807161

Key words

Search

Navigation